Streetbeat News

Products Services

PMN

ProMIS Neurosciences has chosen PMN400 as its lead vaccine candidate to target multiple synucleinopathies, including Multiple System Atrophy, Parkinson's Disease, and Lewy Body Dementia.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:35 pm

ACIU

RHHBY

AC Immune SA will regain all global rights to its Alzheimer's treatment candidates, crenezumab and semorinemab, after the termination of its collaboration agreements with Genentech, a member of the Roche group. This follows Genentech's decision to return the rights to AC Immune, which could impact the future development and potential commercialization of these drugs.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:33 pm

CARA

Cara Therapeutics is reallocating its resources to concentrate on the oral difelikefalin Phase 2/3 program for treating notalgia paresthetica. The company is also reducing its operating expenses, which will extend its cash runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:30 pm

ATHE

Alterity Therapeutics, a biotech company focusing on neurodegenerative diseases, has issued a shareholder letter detailing their 2023 achievements and 2024 goals. They reported hitting all 2023 milestones, particularly in Multiple System Atrophy (MSA) research. Their lead candidate, ATH434, has shown promise in pre-clinical studies and has been granted Orphan Drug Designation by the U.S. FDA and the European Commission. Two Phase 2 trials are underway, with topline results from the ATH434-201 study expected in January 2025 and preliminary data from the ATH434-202 study expected in the first half of 2024. Promising data from a Parkinson's disease primate model was also presented, supporting the potential of ATH434 in treating Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:29 pm

DORM

Dorman Products, Inc. has launched over 3,000 new products in 2023 and is starting the new year with an announcement of 325 new motor vehicle parts. This expansion of their product line could indicate a focus on growth and meeting market demand for vehicle parts.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:28 pm

CDE

Coeur Mining has announced an update on its exploration activities at the Silvertip polymetallic project in Northern British Columbia, reporting high-grade intersections of silver, lead, and zinc. The company provided a recap of its 2023 exploration program and offered a preview of its plans for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:17 pm

AUTL

The FDA has accepted Autolus Therapeutics' marketing application for Obecabtagene Autoleucel, a treatment for relapsed/refractory adult B-cell acute lymphoblastic leukemia. The target action date for the FDA's decision is November 16, 2024.

Portfolio Pulse from Charles Gross

January 22, 2024 | 12:16 pm

HLT

Hilton (HLT) reported the opening of 132 hotels and approximately 24,000 rooms in Q4 2023, leading to a total of 395 hotel openings and around 63,000 rooms for the year. This expansion resulted in a net unit growth of 4.9% for the company.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:15 pm

IONS

Ionis Pharmaceuticals announced positive topline results from the Phase 3 OASIS-HAE study of Donidalorsen for treating Hereditary Angioedema, meeting the primary endpoint of reducing the rate of angioedema attacks compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:12 pm

CGNT

Cognyte Software has announced a new release of its LUMINAR Cyber Threat Intelligence product, which now includes GenAI capabilities. This enhancement aims to provide additional value to customers by improving the product's ability to identify and respond to cyber threats.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:09 pm